Does Ketamine Show on a Drug Test?

Ketamine can absolutely show up on a drug test, but whether it actually does depends on which test is being run. The standard five-panel urine drug screen used for most workplace and federal testing does not include ketamine at all. That screen looks for marijuana, cocaine, amphetamines, opiates, and PCP. So in many routine testing situations, ketamine will go completely unnoticed. When an employer, court, or treatment program specifically orders a panel that targets ketamine, though, the drug and its breakdown products are readily detectable in urine, saliva, and hair, sometimes for surprisingly long periods.

Why Most Workplace Drug Tests Do Not Catch Ketamine

The federal workplace testing guidelines established by the Substance Abuse and Mental Health Services Administration (SAMHSA) mandate screening for five drug classes: amphetamines, cannabinoids (THC), cocaine, opioids, and phencyclidine (PCP). The Department of Transportation follows the same five-panel standard for safety-sensitive positions like truck drivers and airline pilots. Since ketamine is not one of those five categories, a person who has used ketamine could test negative on a standard federal or corporate drug screen.

That said, many private employers, military branches, pain clinics, and criminal justice programs use expanded panels that go beyond the federal minimum. These extended tests, sometimes called 10-panel or 12-panel screens, can include ketamine alongside benzodiazepines, barbiturates, methadone, and other substances. If you are unsure whether the test you are facing includes ketamine, the testing panel is almost always listed on the chain-of-custody form or can be clarified with the ordering provider. Assume nothing.

There is also a quirk worth knowing about: ketamine’s chemical structure is related to PCP, and older immunoassay-based PCP screening tests have been known to cross-react with ketamine. In other words, ketamine use can occasionally trigger a false positive on the PCP line of a standard panel, even though ketamine is not the target. This does not happen reliably enough that every ketamine user will flag positive for PCP, but it does mean the drug is not completely invisible to standard screens.

How Long Ketamine Stays in Urine

Urine is the most common sample type for drug testing, and the detection window for ketamine in urine varies a lot depending on the analytical method used and the individual person’s metabolism. In a study of pediatric patients receiving therapeutic ketamine doses, the parent drug was found in urine for up to 11 days using one analytical technique, while its primary metabolite, norketamine, lingered for up to 14 days using another method.¹ The researchers noted that the detection window is “highly dependent on the method used for determination and varies between individuals,” which is an important caveat. One testing lab might catch ketamine that another would miss, purely because of how sensitive the equipment is.

A separate analysis using ultra-high-pressure liquid chromatography confirmed ketamine in urine for up to five days and norketamine for up to six days. A third metabolite, dehydronorketamine, was detectable for up to ten days, offering what the researchers described as a very broad detection window.² Dehydronorketamine tends to accumulate at higher concentrations in urine than ketamine itself, which makes it a useful marker when labs are looking for evidence of ketamine use even days after the drug has worn off.³

In practical terms, if you used ketamine once at a moderate dose, your urine would likely test clean within a few days under a typical screening immunoassay. But if the lab uses highly sensitive mass spectrometry methods or targets metabolites, traces could persist for a week or longer. Repeated or heavy use pushes the detection window further out because the drug accumulates in body tissues and takes longer to clear.

Oral Fluid and Saliva Testing

Oral fluid testing is becoming more common, especially in roadside testing by law enforcement and in some workplace programs. A large French study examined oral fluid samples from drivers who tested positive for ketamine and found a wide range of concentrations, from as low as 0.15 ng/mL to over 16,000 ng/mL.⁴ Among the drivers who self-reported their time of last use, the average was about 48 hours before the sample was collected, though the range stretched from 30 minutes to over 17 days.

Oral fluid picks up both the parent drug and norketamine. In about 60% of the positive samples in that study, both ketamine and norketamine were present together, and those cases tended to involve much higher ketamine concentrations. When norketamine was absent, ketamine levels were consistently below 50 ng/mL, suggesting those were cases where either a long time had passed since use or the dose was small. The takeaway is that saliva tests can catch ketamine for at least a couple of days after use, and possibly much longer depending on how much was taken and how sensitive the assay is.

Hair Follicle Testing

Hair testing offers the longest detection window of any sample type. As drugs circulate through your bloodstream, small amounts get deposited into the growing hair shaft. Since head hair grows roughly one centimeter per month, a standard three-centimeter hair sample represents about three months of history.

A case study of a 22-year-old woman who received three intravenous ketamine doses totaling 171 mg for depression treatment found that ketamine was detectable in the hair segment corresponding to the treatment period at 58 pg/mg. Even four months after treatment ended, ketamine was still measurable in hair closer to the scalp, although at a concentration that had dropped by 97%. The estimated elimination half-life in hair was just under one month, and the authors projected that ketamine should become undetectable roughly seven months after the last dose.⁵ Keep in mind that this was a patient who received a relatively small total dose in a medical setting. Recreational users who take larger or repeated doses would likely show higher concentrations that persist even longer.

Hair analysis is also used in forensic investigations, particularly in suspected drug-facilitated crimes. Segmental hair testing can reconstruct a timeline of drug exposure after the fact, and ketamine is among the drugs most commonly identified in that context.⁶ Modern mass spectrometry methods can detect drugs in hair at picogram-per-milligram levels, meaning even a single dose can leave a trace.

Blood Testing

Blood (or plasma/serum) testing for ketamine is primarily used in hospital emergency settings and forensic investigations rather than workplace drug screens. Ketamine has a relatively short half-life in blood, roughly two to three hours for the parent drug, so blood concentrations drop quickly after the last dose. Norketamine lingers a bit longer in blood since the body converts ketamine into it as part of normal metabolism. In practice, blood is useful for determining whether someone is currently under the influence, not for catching use from days or weeks prior. If you are being tested for ketamine in a clinical context, such as after arriving at an emergency department, a blood draw is a common approach.

False Positives and Medications That Interfere

Immunoassay-based screening tests, the rapid-turnaround tests typically used as a first pass, work by detecting antibodies that bind to a drug or its metabolites. These antibodies are not perfectly specific. They can sometimes bind to chemically similar substances, producing a positive result for a drug the person never actually took.

One documented cause of false-positive ketamine screens is quetiapine, an antipsychotic medication sold under the brand name Seroquel. A case report described two patients taking quetiapine who initially screened positive for ketamine on a urine immunoassay but were confirmed negative on follow-up testing.⁷ If you take quetiapine and face a drug test that includes ketamine, this is worth flagging to the medical review officer or testing provider in advance. The issue resolves with confirmatory testing, but the initial positive can cause unnecessary stress and suspicion.

As mentioned earlier, the structural similarity between ketamine and PCP can also lead to cross-reactivity on PCP immunoassays. Someone who has used ketamine but not PCP might flag positive on the PCP line of a standard panel. Again, confirmatory testing will sort this out, but the initial result can be alarming. If you are prescribed ketamine for any medical reason, having documentation ready is a practical safeguard.

How Confirmatory Testing Works

A positive result on an initial immunoassay screen is not the end of the story. Any reputable drug testing program will send the sample for confirmatory analysis before reporting a final result. Confirmation is typically done using mass spectrometry methods, either gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS). These techniques identify specific molecules by their mass-to-charge ratio, so they can distinguish ketamine from structurally similar drugs that might fool an immunoassay.

Confirmatory testing also identifies specific metabolites. When a lab reports the presence of both ketamine and norketamine in a urine sample, that pattern is consistent with actual ketamine ingestion rather than a cross-reacting substance. Some labs also look for dehydronorketamine, which, as noted earlier, accumulates to the highest concentration in urine among the three main analytes and can extend the detection window. One technical challenge researchers have noted is that the structural similarity between norketamine and dehydronorketamine can cause measurement errors if the analytical method is not carefully tuned, potentially leading to overestimation of norketamine levels.⁸ In practice, this is a concern for lab scientists optimizing their methods, not something the person being tested needs to worry about directly.

Therapeutic Ketamine and What It Means for Drug Testing

The rapid expansion of ketamine-based treatments for depression, chronic pain, and PTSD has created a new population of people who use ketamine legally, under medical supervision, and who may face routine drug screening. Ketamine infusion clinics have proliferated across the United States, and the FDA-approved nasal spray esketamine (Spravato) is prescribed for treatment-resistant depression. These patients are using a Schedule III controlled substance with a legitimate prescription, and they deserve clarity about how this intersects with drug testing.

If your employer uses a standard five-panel test, your prescribed ketamine use is unlikely to appear at all. But if the panel includes ketamine or if cross-reactivity causes a PCP flag, you will need documentation. A prescription from your treating provider, plus records from the infusion clinic or pharmacy, establishes that your positive result reflects legal medical use. In federally regulated testing programs, a Medical Review Officer (MRO) reviews all positive results before they are reported to the employer. The MRO’s role is to determine whether there is a legitimate medical explanation for the result, and a valid ketamine prescription qualifies.

The trickier scenario involves employers or programs that have zero-tolerance policies for certain substances regardless of prescription status. Some safety-sensitive jobs may prohibit the use of ketamine, even therapeutically, due to its dissociative and sedating effects. If you work in such a role and are considering ketamine treatment, having a conversation with your occupational health provider before starting therapy is a wise move. The legal landscape around this is still evolving, and workplace policies vary widely.

How Dose and Frequency Affect Detection

The detection windows cited in studies often come from controlled settings where patients receive known doses, typically in the range of 0.5 to 2 mg/kg for medical infusions. Recreational doses vary wildly and can be substantially higher, especially with repeated dosing over a session or habitual use over weeks. Higher cumulative doses mean more drug and more metabolites stored in body tissues, which translates to a longer window of detection in every sample type.

Route of administration matters too. Intravenous ketamine enters the bloodstream instantly and is metabolized relatively quickly. Intramuscular injection is absorbed somewhat more slowly. Intranasal use (snorting) provides rapid absorption through nasal mucosa but also leaves residue in the nasal and oral cavities that can be picked up on oral fluid tests. Oral ketamine, whether as a prescribed lozenge or swallowed powder, undergoes extensive first-pass metabolism in the liver, producing proportionally more norketamine relative to the parent drug. This shift in the metabolite profile can affect which compounds a test detects and how the results are interpreted.

Body composition, liver function, hydration status, and concurrent medication use all influence how quickly ketamine clears. People with impaired liver function metabolize the drug more slowly, extending the detection window. There is no reliable way to predict the exact day your urine or hair will test clean, which is why the timelines in research papers are always presented as ranges rather than fixed numbers.

Designer Analogs and Testing Blind Spots

Ketamine’s popularity as a recreational drug has spawned several designer analogs, substances engineered to produce similar dissociative effects while evading standard detection methods. The most well-known is methoxetamine (MXE), which gained traction in the early 2010s. Methoxetamine is not picked up by standard urine drug tests, and at the time of its emergence, no reliable laboratory test existed for routine detection.⁹ Specialized forensic labs can now identify methoxetamine and other ketamine-like compounds using targeted mass spectrometry, but most clinical and workplace testing panels still do not include them.

Other analogs such as deschloroketamine, 2-fluorodeschloroketamine, and various arylcyclohexylamine derivatives have appeared on the recreational market. These substances present a moving target for testing programs. Some of them can cross-react with immunoassays designed for ketamine or PCP, producing unpredictable screening results, while others fly completely under the radar. For law enforcement and military drug testing programs, this represents an ongoing challenge, and it is one reason forensic toxicology labs continue to develop broader screening panels that can catch novel psychoactive substances.

What a Positive Ketamine Result Actually Tells You

A positive urine screen for ketamine tells you that the person was exposed to the drug within the recent past, but it does not tell you when the drug was taken, how much was used, or whether the person was impaired at the time of collection. Urine testing detects metabolites that may linger long after the psychoactive effects have worn off. A person who received a single ketamine infusion for depression five days ago could test positive on a sensitive urine assay while being completely sober and functional.

Hair testing offers a timeline but not precise dosing information. The concentration of ketamine found in a hair segment reflects a rough average of exposure during the period that segment was growing, not a single event. Forensic hair analysis is useful for establishing patterns of exposure, such as whether drug use was a one-time event or ongoing, but it is not appropriate for determining acute impairment.

Oral fluid testing comes closest to correlating with recent use and potential impairment, since the drug appears in saliva shortly after intake and clears relatively quickly. But even oral fluid results have to be interpreted carefully, particularly when the person has a legitimate prescription. The growing medical use of ketamine means that positive test results are becoming more common in populations that were never on the radar before, and testing programs are still catching up with how to handle that shift.